Ophthalmology

The AJMC® Ophthalmology compendium is a comprehensive resource for clinical news and expert insights for treatment of disorders of the eye.

Latest News

Man using eye drops | Image credit: 9nong - stock.adobe.com
Dry Eye Awareness Month Highlights Condition Affecting Millions

July 8th 2025

Dry eye affects up to 16 million people in the US, and new treatments aim to mitigate the symptoms that can disrupt quality of life in these patients.

Man applying eye drops | Image credit: StockImageFactory
Education Surrounding Dry Eye a Persistent Barrier in Treatment

July 8th 2025

Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease

July 7th 2025

Dry eye | Image credit: Kryuchka Yaroslav - stock.adobe.com
Tear Film Instability More Severe in Patients With Dry Eye, Diabetes

July 2nd 2025

Older adult eyes | Image credit: michaelheim - stock.adobe.com
iAMD Progression Linked to Dysregulation of Complement Pathways

June 25th 2025

Continuing Medical Education
View All
July 14th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 14th 2025

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry
July 14th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 14th 2025

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

1.5 Credits / Ophthalmology/Optometry
July 14th 2025

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

1.5 Credits / Ophthalmology/Optometry
July 14th 2025

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)

1.5 Credit / Ophthalmology/Optometry
July 14th 2025

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

1.5 Credit / Ophthalmology/Optometry

More News

Older man with glasses
April 26th 2023

Average Acuity-Based Outcomes Improved With Eyeglasses Using 0.05D Steps

Julia Bonavitacola
Researchers found that eyeglasses with traditional steps of 0.25D were less effective and less preferred by participants compared with those refracted in 0.05D steps.
Screenshot of Charles Wykoff, MD, PhD
April 23rd 2023

Dr Charles Wykoff Discusses Gene Therapy to Treat Wet Age-Related Macular Degeneration

Laura Joszt, MA
Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.
Baby
April 17th 2023

ROP Incidence Increased in Premature Infants

Julia Bonavitacola
Retinopathy of prematurity (ROP) was found to have increased from 2003 to 2019, especially in Black and Hispanic children.
Headshot of Darius Moshfeghi, MD
April 17th 2023

Dr Darius Moshfeghi Outlines the Impact of Delayed Treatment in ROP

Laura Joszt, MA
Retinopathy of prematurity (ROP) that occurs in preterm babies can progress fast, which requires quick decisions early about treatment, explained Darius M. Moshfeghi, MD, chief, Retina Division, and professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine.
Eye
April 12th 2023

Perfluorohexyloctane Reduced Signs and Symptoms of Dry Eye Disease

Julia Bonavitacola
Perfluorohexyloctane (NOV03) was able to reduce the signs and symptoms of dry eye disease (DED) when compared with hypotonic saline control and was well tolerated.
Screenshot of Charles Wykoff, MD, PhD
April 10th 2023

Dr Charles Wykoff: Some Patients May Need Both Gene Therapy and Anti-VEGF to Treat Wet AMD

Laura Joszt, MA
While there are benefits of gene therapy, some patients will continue to need anti–vascular endothelial growth factor (VEGF) therapy to treat wet age-related macular degeneration (AMD), said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.
Money
April 3rd 2023

First-year Single Eye Treatment Cost Lowest With Bevacizumab for AMD, DME

Julia Bonavitacola
Treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME) for a single year was found to be lowest when using bevacizumab.
Screenshot of Jennifer Sun, MD, MPH
April 3rd 2023

Switching From Aflibercept to Bevacizumab Results in Cost Savings Without Sacrificing Visual Acuity, Says Dr Jennifer Sun

Laura Joszt, MA
The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Trajectory of Treatment Landscape for Wet AMD and DME
March 30th 2023

Trajectory of Treatment Landscape for Wet AMD and DME

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.
Payer Engagement With the Retina Community
March 30th 2023

Payer Engagement With the Retina Community

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.
Screenshot of Eleonora Lad, MD, PhD, smiling
March 26th 2023

Dr Eleonora Lad: Early Intervention for Geographic Atrophy Prevents Too Much Irreversible Damage

Laura Joszt, MA
The first FDA-approved therapy for geographic atrophy, pegcetacoplan, slows disease progression but does not reverse it, which means providers need to intervene early before there is too much irreversible damage, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Evolution of Access to Treatment for Wet AMD/DME Therapies
March 23rd 2023

Evolution of Access to Treatment for Wet AMD/DME Therapies

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.
Wet AMD Resource Utilization Impacted by Medication Duration of Action
March 23rd 2023

Wet AMD Resource Utilization Impacted by Medication Duration of Action

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.
Eye
March 21st 2023

Estimates of Diabetic Retinopathy Incidence, Progression Lower Than Previously Reported in American Indians

Julia Bonavitacola
American Indians and Alaska Native individuals had lower estimates of incidence of diabetic retinopathy than had been reported.
Utilization Management Strategies in Treatment of Wet AMD and DME
March 16th 2023

Utilization Management Strategies in Treatment of Wet AMD and DME

Veeral Sheth, MD, MBA, FACS, Joseph Coney, MD, FASRS, FACS, and Caesar Luo, MD, FASRS, FACS discuss their experience with utilization management strategies.
Treatment Barriers Facing Patients With DME and Wet AMD
March 16th 2023

Treatment Barriers Facing Patients With DME and Wet AMD

Caesar Luo, MD, FASRS, FACS discusses the biggest barriers for patients with wet AMD and DME to receiving optimal treatment and his strategies to overcome these barriers.
Woman with eye drops
March 15th 2023

Treatments for DED Associated With MGD Require Future Evaluation, Development

Julia Bonavitacola
A systematic review found that there were currently a limited number of clinical trials evaluating treatment for dry eye disease (DED) that is associated with meibomian gland dysfunction (MGD).
Woman's eyes
March 9th 2023

Faster Rates of GCIPL, cpRNFL Thinning Associated With Higher Risks of Glaucoma

Julia Bonavitacola
Ganglion cell/inner plexiform layer (GCIPL) and circumpapillary retinal nerve fiber layer (cpRNFL) thinning were both associated with a higher risk of developing perimetric glaucoma.
Diagnostic Imaging Impacting DME and Wet AMD Treatment Landscape
March 9th 2023

Diagnostic Imaging Impacting DME and Wet AMD Treatment Landscape

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.
Novel Treatment Mechanisms for Patients with DME and Wet AMD
March 9th 2023

Novel Treatment Mechanisms for Patients with DME and Wet AMD

Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.
Screenshot of Eleonora Lad, MD, PhD, smiling during a Zoom video interview
March 5th 2023

Pegcetacoplan Approval a “Dream Come True” for Patients With Geographic Atrophy, Says Dr Eleonora Lad

Laura Joszt, MA
Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Clinical Considerations for Retreatment in Failed Anti-VEGF Therapy
March 2nd 2023

Clinical Considerations for Retreatment in Failed Anti-VEGF Therapy

Veeral Sheth, MD, MBA, FACS discusses re-treatment in patients with wet AMD who have previously failed an anti-VEGF therapy.
Faricimab Approved Label Dosing Interval
March 2nd 2023

Faricimab Approved Label Dosing Interval

Dr Coney expands on the role and impact of approved label dosing of faricimab.
Eye with technology overlay
March 2nd 2023

Amsler Grid Test Not Recommended for Early AMD Detection

Julia Bonavitacola
A recent review found that the performance of the Amsler grid test was not at a level that was recommended for detecting early or dry age-related macular degeneration (AMD).
Baby in mother's arms
March 1st 2023

Cataract Surgery in Children Commonly Led to Glaucoma-Related Adverse Events

Julia Bonavitacola
The Pediatric Eye Disease Investigator Group collected data on children who had lensectomy prior to age 13 years in a 5-year span.
Richard Allen, MD, PhD, FACS
February 24th 2023

Dr Richard Allen Discusses Oculoplastic Surgery in Pediatric Patients

Skylar Jeremias Julia Bonavitacola
Richard Allen, MD, PhD, FACS, professor at Baylor College of Medicine, reviewed the challenges of oculoplastic surgery in pediatric patients.
Faricimab: Mechanism of Action, Payers’ Perspective, and Real-World Experience
February 23rd 2023

Faricimab: Mechanism of Action, Payers’ Perspective, and Real-World Experience

Key opinion leaders discuss faricimab, its impact on the treatment landscape for wet AMD/DME, and what payers should look for when considering formulary positioning or utilization-management strategies.
Variability of Frequency Dosing for Anti-VEGF Agents in the Treatment of Wet AMD
February 23rd 2023

Variability of Frequency Dosing for Anti-VEGF Agents in the Treatment of Wet AMD

Dr Coney discusses the variability of frequency dosing with anti-VEGF therapy in patients with wet AMD and DME, and Dr Sheth expands on Ang-2 and its contribution to the development of vascular instability in wet AMD.
Older woman's eye
February 22nd 2023

Visual Impairment Associated With Negative Effects on Older Adults With Dementia

Julia Bonavitacola
A review found that visual impairment is common in older adults with dementia and associated with negative effects.
Red FDA Approved stamp
February 17th 2023

FDA Approves First Treatment for Geographic Atrophy

Laura Joszt, MA
Geographic atrophy is a leading cause of blindness. The new approval will help to fill an unmet need for patients.
<12345678910
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo